Karen R. Jensen
Medical Practice in Millsboro, DE

License number
Delaware C9-0000081
Issued Date
Nov 10, 1998
Expiration Date
Nov 30, 2018
Category
Medical Practice
Type
Respiratory Practitioner
Address
Address 2
Millsboro, DE 19966

Professional information

Karen Jensen Photo 1

Methods Of Treating And Preventing Neurological Symptoms Caused By Avian Reovirus And Novel Associated Characteristics

US Patent:
2010023, Sep 16, 2010
Filed:
May 25, 2010
Appl. No.:
12/786906
Inventors:
Saskia van de Zande - Boxmeer, NL
Rudolf George Hein - Georgetown DE, US
Donald Eugene Roessler - Bishopville MD, US
Gwenllyan F. Slacum - Millsboro DE, US
Karen L. Jensen - Millsboro DE, US
Phyllis A. Lynch - Millsboro DE, US
Assignee:
Intervet International B.V. - Boxmeer
International Classification:
A61K 39/15, C12N 7/00, A61P 31/12, A61P 37/02
US Classification:
4242151, 4352351
Abstract:
Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise and immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms.


Karen Jensen Photo 2

Methods Of Treating And Preventing Neurological Symptoms Caused By Avian Reovirus And Novel Associated Characteristics

US Patent:
7736847, Jun 15, 2010
Filed:
Oct 9, 2003
Appl. No.:
10/526706
Inventors:
Saskia van de Zande - Geel, BE
Rudolf George Hein - Georgetown DE, US
Donald Eugene Roessler - Bishopville MD, US
Gwenllyan F. Slacum - Millsboro DE, US
Karen L. Jensen - Millsboro DE, US
Phyllis A. Lynch - Laurel DE, US
Assignee:
Intervet International B.V. - Boxmeer
International Classification:
C12Q 1/70, A61K 39/15
US Classification:
435 5, 4242151
Abstract:
Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise an immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms.